MedPath

Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia

Phase 4
Completed
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Registration Number
NCT04585607
Lead Sponsor
Gangnam Severance Hospital
Brief Summary

The current study will investigate whether long term implementation of expanded hemodialysis (HDx) will effectively decrease serum levels of large uremic toxins and ameliorate progression of sarcopenia in patients with chronic kidney disease requiring hemodialysis.

Detailed Description

This is an open-label, prospective, 1:1 randomized, parallel-group, study to evaluate the efficacy of expanded hemodialysis (HDx) compared to conventional hemodialysis in patients with chronic kidney disease in South Korea for up to 12 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
47
Inclusion Criteria
  • On HD treatment over 6 months before study enrollment
  • Aged over 18 years
  • Able to give informed consent
Exclusion Criteria
  1. Hemiplegia or paraplegia state
  2. Planned renal transplant or conversion to peritoneal dialysis within study period
  3. Active chronic infection or inflammatory conditions including autoimmune disease, inflammatory arthritis and active malignancy
  4. History of monoclonal gammopathy
  5. Life expectancy <12 months
  6. Pregnancy or breast feeding
  7. Receiving immunosuppressant medication
  8. Inability to complete study assessments

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Biomarkers of sarcopeniaChanges in serum level of Myostatin and IGF-1 every 6 months

Change in blood levels of myostatin and insulin-like growth factor-1 (IGF-1)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.